NCT07476066Not yet recruitingPhase 1
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma
Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd0 sites374 target enrollmentStarted: March 15, 2026Last updated:
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 374
- Primary Endpoint
- Occurrence of Adverse Events (AE) and Serious Adverse Events (SAE)
Study Overview
Brief Summary
This is a Phase I/II clinical study conducted in participants with relapsed/refractory aggressive B-cell lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SYS6055 Injection in participants with relapsed/refractory aggressive B-cell lymphoma, and to provide a basis for the recommended dosing regimen in subsequent studies.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •1. Age ≥ 18 year, and voluntarily signed the Informed Consent Form (ICF);
- •2. Histologically confirmed aggressive B-cell lymphoma (defined according to the 5th edition of the WHO classification);
- •3. Patients with relapsed/refractory aggressive B-cell lymphoma who failed standard therapy, with CD19-positive tumor cells;
- •4. At least one measurable lesion according to the 2014 Lugano Response Criteria for Lymphoma;
- •5. ECOG performance status score of 0-1;
- •6. Expected survival of at least 3 months;
- •7. Adequate organ and bone marrow function;
- •8. Eligible participants (males and females) of reproductive potential must agree to use a reliable method of contraception (hormonal contraception, barrier method, or abstinence) with their partner during the trial and for at least 1 year after dosing. Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment. In addition, female participants must agree not to donate oocytes (eggs, ova) for assisted reproductive technology for 1 year after dosing, and male participants must agree not to donate sperm for assisted reproductive technology for 1 year after dosing;
- •9. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion Criteria
- •1. History of other malignancy within 3 years or concurrent other active malignancy (participants with cured localized tumors such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, carcinoma in situ of the breast, etc., may be enrolled);
- •2. Participants with bleeding diathesis, active bleeding, hemoptysis, or history of major bleeding within the previous 6 months; tumor invasion of major blood vessels shown by imaging (CT or MRI), or tumor judged by the investigator as highly likely to invade major blood vessels and cause fatal massive bleeding during the subsequent study period;
- •3. Participants with aggressive B-cell lymphoma involving the central nervous system;
- •4. Received autologous hematopoietic stem cell transplantation within 3 months prior to the first dose;
- •5. Previous allogeneic bone marrow transplantation, gene therapy, or adoptive cell therapy (including CAR-T therapy);
- •6. Received anti-PD-1, anti-PD-L1, or T-cell engager therapy within 3 months prior to the first dose; received fludarabine or bendamustine within 6 months prior to the first dose;
- •7. Adverse events from prior antineoplastic therapy have not recovered to CTCAE Version 6.0 grade ≤1 (except for alopecia or other toxicities without safety risk as judged by the investigator);
- •8. Received major surgery, chemotherapy, radical radiotherapy, antibody-based targeted therapy, imunotherapy, or other antineoplastic therapy within 28 days prior to dosing; or received palliative radiotherapy, chemotherapy, or small-molecule targeted therapy within 14 days prior to dosing; or received antineoplastic herbal preparations or traditional Chinese patent medicines within 14 days prior to dosing;
- •9. Simultaneously participating in another clinical trial, unless it is an observational (non-interventional) clinical trial or in the follow-up phase of an interventional trial (without impact on the follow-up data of this study);
- •10. Received live vaccine within 4 weeks prior to dosing;
- •11. Active bacterial, fungal, or viral infection prior to dosing. Individuals receiving prophylactic antimicrobial therapy without clinical manifestations of active infection prior to dosing may be considered for enrollment;
- •12. Autoimmune disease requiring systemic therapy;
- •13. History of central nervous system disease or current persistent central nervous system disease that may interfere with neurological assessments;
- •14. History of immunodeficiency or positive HIV antibody test during screening;
- •15. History of tuberculosis treatment within 2 years prior to dosing; history of active syphilis;
- •16. Active hepatitis B or hepatitis C during screening. Active hepatitis B is defined as HBsAg-positive and HBV DNA above the upper limit of normal (ULN). Active hepatitis C is defined as HCV antibody-positive and HCV RNA > ULN;
- •17. History of severe cardiovascular disease;
- •18. Hypersensitivity or intolerance to the excipients of SYS6055 (mainly human albumin);
- •19.Any other conditions in participants that may interfere with compliance with study procedures, are not in the best interest of participants, or may affect study results: e.g., history of psychiatric disorders, drug addiction or substance abuse, any other clinically significant diseases or conditions, etc.;
- •20. Pregnant or lactating female;
- •21. Any other reason judged by the investigator that the participant is not suitable for participation in this clinical trial.
Arms & Interventions
Dose Escalation, Backfill and Cohort Expansion
Experimental
In the dose escalation phase, participants will receive escalating doses of SYS6055. In the roll-in phase and cohort expansion phase, participants will receive selected doses of SYS6055. Participants will be administered a single dose on Day 0 of Cycle 1.
Intervention: SYS6055 (Drug)
Outcomes
Primary Outcomes
Occurrence of Adverse Events (AE) and Serious Adverse Events (SAE)
Time Frame: Up to 24 months after administration of 6055
Recommended Phase 2 Dose (RP2D) or Maximum Tolerated Dose (MTD) of SYS6055
Time Frame: through study completion, an average of 3 years
Dose-limiting toxicities (DLTs)
Time Frame: Dose-limiting toxicities (DLTs) will be assessed 28 days after the first dose.
Secondary Outcomes
- Objective Response Rate (ORR)(through study completion, an average of 3 years)
- Time to Response（TTR ）(through study completion, an average of 3 years)
- Duration of Response (DoR)(through study completion, an average of 3 years)
- Progression-free survival (PFS)(through study completion, an average of 3 years)
- Overall Survival (OS)(hrough study completion, an average of 3 years)
- PK CD19-CAR copy number and CD19 CAR-T cell content of SYS6055(2 years)
- PK，CD19 CAR-T cell phenotypes(2 years)
- PD(2 years)
- Immunogenicity,(2 years)
- Viral shedding(2 years)
- Replication-competent virus detection(2 years)
- Viral integration site analysis(2 years)
Investigators
Similar Trials
Recruiting
Phase 2
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCCNCT07422753Second Affiliated Hospital, School of Medicine, Zhejiang University36
Not yet recruiting
Phase 1
Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic AnemiaSevere Aplastic AnemiaNCT07297550Institute of Hematology & Blood Diseases Hospital, China42
Not yet recruiting
Not Applicable
To Evaluate the Safety and Tolerability of STR-P004 for the Treatment of Immune-mediated Kidney DiseasesNCT07363954Starna Therapeutics9
Enrolling By Invitation
Phase 1
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UCBladder Urothelial CarcinomaLymph Node MetastasisNCT07353294Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University12
Completed
Phase 2
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid TumorsRenal Cell CarcinomaNon-Small Cell Lung Cancer2022-500694-14-00Beigene Ltd., Beigene Ltd.48